Shots:
- Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseases
- As per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field option payments, plus net sales-based tiered royalties. Global development will be partially co-funded, with Alumis retaining rights in other regions
- ESK-001 is being investigated in P-IIb trial for SLE & P-III (ONWARD) program for 24wks., incl. 2 P-III (ONWARD1 & 2) trials for mod. to sev. Plaque PsO, after which pts could opt for an LTE study
Ref: Globenewswire | Image: Alumis & Kaken
Related News:- Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
